万维提示：
1、投稿方式：在线投稿。
2、期刊网址：https://journals.sagepub.com/home/cpt
3、投稿网址：https://mc.manuscriptcentral.com/jcpat
4、官网邮箱：supriya.bidola@sagepub.in
5、期刊刊期：双月刊，逢单月出版。
2021年7月15日星期四
投稿须知【官网信息】
Manuscript Submission Guidelines:
Please read the guidelines below then visit Journal of Cardiovascular Pharmacology and Therapeutics (JCPT)’s submission site at https://mc.manuscriptcentral.com/jcpat to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned. Remember you can log in to the submission site at any time to check on the progress of your paper through the peer review process.
SAGE Publishing disseminates high-quality research and engaged scholarship globally, and we are committed to diversity and inclusion in publishing. We encourage submissions from a diverse range of authors from across all countries and backgrounds.
Only manuscripts of sufficient quality that meet the aims and scope of JCPT will be reviewed.
As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere. Please see our guidelines on prior publication. Note that JCPT may accept submissions of papers that have been posted on pre-print servers; please state in the Submission Letter that the manuscript has been posted on a pre-print server, and include the DOI for the preprint in both the Submission Letter and in the designated field in the manuscript submission system. Authors are not permitted to post an updated version of their paper on the preprint server while it is being peer reviewed for possible publication in the journal. If the article is accepted for publication, the author may re-use their work according to the journal's author archiving policy. If your paper is accepted, you must include a link on your preprint to the final version of your paper.
This Journal is a member of the Committee on Publication Ethics.
This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).
There are no fees payable to submit or publish in this journal.
If you have any questions about publishing with SAGE, please visit the SAGE Journal Solutions Portal.
1. What do we publish?
1.1 Aims & Scope
Before submitting your manuscript to JCPT, please ensure you have read the Aims & Scope.
Journal of Cardiovascular Pharmacology and Therapeutics is a peer-reviewed journal that publishes original basic human studies, original animal studies, and original bench research with potential clinical application to cardiovascular pharmacology and therapeutics. The focus of the experimental studies is translational research. The journal also publishes review articles on basic research, clinical research, editorials, commentaries, points of view, and controversies. Selected journal supplements will also be published. Future focus will include cardioprotective therapies, stem cell therapy, regenerative cardiology, therapies for preventive cardiology (risk factor management), and antiarrhythmic therapies.
1.2 Article Types
JCPT publishes both original clinical studies and original preclinical investigations with clear translational relevance. Areas of interest include (but are not limited to) cardioprotective therapies, stem cell therapy, regenerative cardiology, therapies for preventive cardiology (risk factor management), as well as antiplatelet, anticoagulation and antiarrhythmic therapies.
Meta-analyses, Systematic Reviews, Editorials, Commentaries and Letters to the Editor will be given low priority and will be considered for publication on a highly selective basis. Case reports will not be accepted.
For preclinical investigation, priority will be given to in vivo studies that focus on pharmacologic therapy for disease models. In general isolated cell studies alone, without an in vivo component, will be given low priority. All research involving animals must adhere to the ARRIVE2 Guidelines: see Section 2.8. Failure to comply with these Guidelines will result in rejection of the manuscript.
Isolated cell studies alone, without an in vivo component, will be given low priority. JCPT will not consider studies of herbal remedies: these contributions should be submitted to journals of alternative medicine.
JCPT accepts the following article types:
Original Manuscripts
Manuscripts should be written clearly and concisely: maximum 6,000 words (including Abstract, Figure Legends and References)
200-250 word structured abstract
5-6 keywords
Maximum 50 references
Reviews
Reviews should be written clearly and concisely: maximum 7,500 words (including Abstract, Figure Legends and References)
200-250 word structured abstract
5-6 keywords
Maximum 100 references
Letters to the Editor
Letters are considered for publication on a highly selective basis, and must comment on a recent paper published in JCPT
Letters reporting original data will not be accepted
Maxium 1,000 words (including References)
No abstract
3-4 keywords
Maximum 5 references
1.3 Writing your paper
The SAGE Author Gateway has some general advice and on how to get published, plus links to further resources.
1.3.1 Make your article discoverable
For information and guidance on how to make your article more discoverable, visit our Gateway page on How to Help Readers Find Your Article Online.
2. Editorial policies
2.1 Peer review policy
JCPT operates a conventional single-blind reviewing policy in which the reviewer’s name is always concealed from the submitting author.
Decisions on manuscripts will be taken as rapidly as possible. In general, Editors will seek advice from two or more expert reviewers about the scientific content and presentation of submitted articles.
The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor/Board member will have no involvement in the decision-making process.
JCPT is committed to delivering high quality, fast peer-review for your paper, and as such has partnered with Publons. Publons is a third party service that seeks to track, verify and give credit for peer review. Reviewers for JCPT can opt in to Publons in order to claim their reviews or have them automatically verified and added to their reviewer profile. Reviewers claiming credit for their review will be associated with the relevant journal, but the article name, reviewer’s decision and the content of their review is not published on the site. For more information visit the Publons website.
2.2 Authorship
Papers should only be submitted for consideration once all contributing authors give consent. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.
The list of authors should include all those who can legitimately claim authorship. This is all those who:
Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
Drafted the article or revised it critically for important intellectual content,
Approved the version to be published,
Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
Authors should meet the conditions of all of the points above. When a large, multicenter group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.
2.3 Acknowledgements
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.
2.3.1 Third party submissions
Where an individual who is not listed as an author submits a manuscript on behalf of the author(s), a statement must be included in the Acknowledgements section of the manuscript and in the accompanying cover letter. The statements must:
Disclose this type of editorial assistance – including the individual’s name, company and level of input
Identify any entities that paid for this assistance
Confirm that the listed authors have authorized the submission of their manuscript via third party and approved any statements or declarations, e.g. conflicting interests, funding, etc.
Where appropriate, SAGE reserves the right to deny consideration to manuscripts submitted by a third party rather than by the authors themselves.
2.3.2 Writing assistance
Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance. It is not necessary to disclose use of language polishing services.
2.4 Funding
JCPT requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: “This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.”
2.5 Declaration of conflicting interests
It is the policy of JCPT to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.
Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that: “The Author(s) declare(s) that there is no conflict of interest.” For guidance on conflict of interest statements, please see the ICMJE recommendations here.
2.6 Research ethics and patient consent
Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki. A statement that the protocol and informed consent were reviewed and approved by an IRB (Institutional Review Board) should be included in the methods section.
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.
For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.
Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative. Please do not submit the patient’s actual written informed consent with your article, as this in itself breaches the patient’s confidentiality. The Journal requests that you confirm to us, in writing, that you have obtained written informed consent but the written consent itself should be held by the authors/investigators themselves, for example in a patient’s hospital record. The confirmatory letter may be uploaded with your submission as a separate file.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants.
All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The journal has adopted the Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals published by the International Association of Veterinary Editors. A statement to this effect needs to be described in the methods section. In addition a statement that the protocol was approved by an IACUC (Institutional Animal Care and Use Committee) is required.
2.7 Clinical trials
JCPT conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrollment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract. The registration number and registry name for clinical trials should be provided in the methods section.
2.8 Reporting guidelines
The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplemental file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplemental file. The EQUATOR wizard can help you identify the appropriate guideline. For all research involving animals, authors must include a sentence in the Methods section of the manuscript, affirming that all investigations adhere to the ARRIVE2 Guidelines. Failure to comply with the ARRIVE Guidelines will result in rejection of the manuscript
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.
2.9 Research data
The journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the SAGE Research Data policy pages.
Subject to appropriate ethical and legal considerations, authors are encouraged to:
share your research data in a relevant public data repository
include a data availability statement linking to your data. If it is not possible to share your data, we encourage you to consider using the statement to explain why it cannot be shared.
cite this data in your research
3. Publishing Policies
3.1 Publication ethics
SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.
3.1.1 Plagiarism
JCPT and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.
In order to help assure that all manuscripts are original submitted papers are routinely screened using a computerize plagiarism tracking system known as iThenticate. This program identifies phrases, sentences, and paragraphs that have previously been published, including the authors' own work. The program generates a similarity index. If the similarity index is greater than ~33% after removal of the bibliography, the manuscript will be returned to the authors without a review.
3.1.2 Prior publication
If material has been previously published it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.
3.2 Contributor's publishing agreement
Before publication, SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. SAGE’s Journal Contributor’s Publishing Agreement is an exclusive licence agreement which means that the author retains copyright in the work but grants SAGE the sole and exclusive right and licence to publish for the full legal term of copyright. Exceptions may exist where an assignment of copyright is required or preferred by a proprietor other than SAGE. In this case copyright in the work will be assigned from the author to the society. For more information please visit the SAGE Author Gateway.
3.3 Open access and author archiving
Journal of Cardiovascular Pharmacology and Therapeutics offers optional open access publishing via the SAGE Choice programme. For more information on Open Access publishing options at SAGE please visit SAGE Open Access. For information on funding body compliance, and depositing your article in repositories, please visit SAGE’s Author Archiving and Re-Use Guidelines and Publishing Policies.
4. Preparing your manuscript for submission
4.1 Formatting
The preferred format for your manuscript is Word.
Manuscripts are accepted for consideration on the condition that they are contributed solely to JCPT. No substantial part of a paper may have been published elsewhere, including being published in another language besides English, except as a scientific abstract. All work must be original. Previously published long phrases, sentences, and paragraphs (including the author’s own work) must be properly cited in AMA format—anything else will be considered unacceptable. A direct quote of no more than 4 lines from textual material should be enclosed in double quotation marks; if longer than 4 lines it should be formatted as a block extract. Always verify the quote against the original source, and the citation should include the exact page number(s) of the source. Such directly quoted material should be used sparingly. The receipt of your manuscript by the Journal will be acknowledged and a decision regarding its status made as soon as possible. All manuscripts are subject to editorial review. Manuscripts must be written in acceptable English. Manuscripts submitted in poor English will be returned without review. Some manuscripts that are deemed inappropriate for the journal or very low priority by the editorial staff may be returned without review.
Submission Letter
The manuscript must be accompanied by a cover letter that states (1) all the authors have read and approved the final manuscript, (2) all authors have read and approve of the data being presented in the manuscript, and (3) the full name, address, e-mail address, phone, and fax number of the individual to whom correspondence concerning the manuscript is to be sent. The cover letter must also specifically state and verify that the paper being submitted has not been previously published in whole or in part in any form, including being published in another language besides English, is not under consideration for publication elsewhere, and is original. If the manuscript has been posted on a pre-print server, this must be acknowledged and the DOI for the preprint must be included in the cover letter. The cover letter should be addressed to
Karin Przyklenk, PhD
Editor-in-Chief
Journal of Cardiovascular Pharmacology and Therapeutics
Wayne State University School of Medicine
Detroit, MI
Title Page
On the title page, please include all of the following information:
The names, degrees, and professional affiliation (position, department, institution, place) of all authors.
The name of the institution where the work reported was done.
Acknowledgment of grant support when appropriate.
Complete mailing address, telephone, and fax of corresponding author and e-mail addresses of all authors.
The American Medical Association (AMA) Manual of Style, is the standard source of style. For more information on the AMA Manual of Style, please visit http://www.amamanualofstyle.com/.
Abstract
The abstract should be no longer than 250 words in length. The abstract should summarize the main points of the paper and be descriptive, narrative, and informative and should include only information that is in the article. Avoid abbreviations. At the bottom of the abstract, please also submit a maximum of 5 keywords for your article.
Body of the Text
For most original manuscripts, the subheadings Introduction, Methods and Materials, Results, Discussion, and Conclusion or Summary are suggested. The introduction should be no longer than 2-3 paragraphs and should provide background and rationale for the study and specifically state the purpose of the study. The methods section should describe what statistical tests were used. The text of the paper should be no longer than 15-20 double-spaced typed pages in most cases. All tables and figures should be referenced in the main text in the order in which they appear. The discussion should stress what is new in the paper and relate the author’s findings to the existing literature. The discussion should show how the findings add to the existing knowledge base of the subject under study.
Abbreviations
Please avoid excessive and unnecessary abbreviations. Keep them to a minimum. The first time an abbreviation is used it should be defined.
Tables
All tables must be cited in text. Tables are to be numbered with Arabic numerals (Table 1, Table 2) in order of their text citation. Each table should be typed (double-spaced throughout) on a separate sheet of paper and should have a title. Use spaces, not vertical rules, to separate columns. Each table should have a legend in sufficient detail to allow understanding without reference to the text.
……
更多详情：
https://journals.sagepub.com/author-instructions/CPT
